LSI’s Post

💸 LSI Alumni raised $1.67 Billion in 2023 💸 We know it’s a big week in our industry, and today we’re thrilled to release our annual LSI Alumni Funding Report — our community-driven resource featuring the 2023 capital raises and M&A deals from the emerging company alumni of our partnering events. In 2023, #LSIAlumni raised more than $1.67 Billion in capital and closed 11 M&A transactions across 117+ total deals. This new spreadsheet indexes these transactions, investors involved (publicly disclosed), and links to our proprietary media and coverage of the companies themselves. 🔗 Click here to see the 2023 LSI Alumni Funding Report: https://lnkd.in/gzSb_tKX We’ve received great feedback on this report from founders, VCs, strategics, and many other executives in Medtech and Healthtech, and look forward to publishing more resources on the news and stories of our growing global community. This easy-to-navigate spreadsheet has all these transactions in one place, so you can focus on building a happier, healthier future. Click the link above to see 117+ LSI Alumni deals from 2023.

#News #JPM24: Several experts on a panel Wednesday at #JPM’s Biotech Showcase expressed positive attitudes for the coming year on the investment side, with Andrew Lam, PharmD, the principal of special investments at Ally Bridge Group, commenting that the panel’s title should be “Biotech in 2024: Let the good times roll.” In all seriousness, Lam noted that there are “signs of life” in the industry. Gabriel Cavazos a senior managing director of investment banking at Leerink Partners, said that while the industry has been through a lot over the last two years, he is ready to see more of a rally in the market. “What’s exciting is despite the hard times in 2023 . . . the last two months of the year have been quite productive, November and December,” noted panelist Maha Katabi, PhD, CFA, general partner at Sofinnova Investments . “We closed the year with 23 M&A deals in the industry. . . . And the last time we exceeded that number was . . . in 2002.” On the #IPO front, Lam noted that more companies could go public as soon as next week and expressed cautious optimism about the prices. This will give investors even more confidence as more capital is being “infused” into the sector. While Lam did say valuations are being compressed and raises are shrinking in deal size compared to previous years, the market is getting better, and sizes are bound to increase. In Cavazos’s view, the IPO front is only just returning to an “equilibrium” stage. Read from from Tyler Patchen and BioSpace using the link in the comments below.

With 2023 in the books, I’m thrilled to release our LSI Alumni Funding Report — featuring the capital raises and M&A deals from the emerging company alumni of our partnering events (LSI USA and LSI Europe). In 2023, #LSIAlumni raised more than $1.67 billion across 106+ deals. Our annual Alumni Funding Report features these transactions and 11 additional M&A deals, investors (publicly disclosed), and links to our proprietary media and coverage of the companies themselves. 🔗 Click here to see the 2023 LSI Alumni Funding Report: https://lnkd.in/djUYnsMK We’ve received great feedback on this report from founders, VCs, strategics, and many other executives in Medtech and Healthtech, and look forward to publishing more resources on the news and stories of our growing global community. If you’re looking for our deeper, comprehensive coverage of emerging companies, deals, global Medtech markets, surgical procedure volumes and more, reach out to me. Our team of US-based career-Medtech market analysts and insiders are here to help you start 2024 intelligently. You’ll also see many of the alumni featured on this report at LSI USA ‘24 this March. We’re less than 12 weeks away and have selected nearly 300 of the most exciting emerging companies in the industry to present to a full house of investors and strategics. See you in Dana Point.

#ICYMI: MedTech Strategist/Market Pathways's own Stephen Levin will be moderating the "Successfully Navigating Exits and Financings in Tough Times" panel discussion between Earlybird Venture Capital's Dr. Christoph Massner and LimFlow SA's Dan Rose at MedTech Europe's The MedTech Forum 2024 on Thursday, May 23 at 10:40AM-11:30AM. Despite a challenging environment for M&A and fundraising amidst an evolving EU regulatory landscape, this panel features strategics, investors and start-up CEOs who are doing deals in spite of these obstacles, and are here to share their strategies in achieving these goals. Lean more here: https://lnkd.in/ex3Y9ySx #MTF2024 #conferences #paneldiscussion #medtech #medtechindustry #medtechinnovation #regulatory

Massachusetts PE Highlights This Week 📈 📍 MPE Partners and Webster Industries teamed up to invest in Allor-Plesh Manufacturing, focusing on aftermarket parts for the steel industry to broaden their product offerings and service capabilities. 📍 SV Health Investors completed a $3 billion acquisition of EyeBio, reinforcing their commitment to biotech innovation and growth with strategic investments. 📍 Bain Capital strengthened its foothold in WealthTech by investing in Envestnet, Inc., known for its advanced AI-driven financial advisory solutions, aiming to expand market leadership and technological advancements. 📍 Audax Private Equity facilitated CW Advisors' acquisition, continuing their strategic growth initiatives in targeted sectors. 📍 Berkshire Partners enabled Harvey Performance Company’s acquisition of ATA, enhancing their precision engineering portfolio and extending their global market reach. 📍 PSG invested in CTERA to bolster its hybrid cloud data management capabilities and advance AI-driven data services, positioning CTERA for accelerated growth and market leadership. #privateequitynews #privateequity #massachussets #rawselection

Making Europe Competitive: Steps Toward a Pan-European Equity Market Ever wondered how Europe can rival the US in software? Henrik Molin, CEO & Co-founder of Physitrack PLC, shares his insights and experiences on leveraging public markets for growth. From Sweden's unique entrepreneurial landscape to six key initiatives that can transform Europe, Henrik's article provides a roadmap for creating a competitive and cohesive Pan-European equity market. Read the full article to explore actionable steps that can drive innovation and growth across Europe. Find the article here: https://lnkd.in/eQHQGDR2 #Boardwave #Makingwaves

Cerebras Systems, a US company which designs and manufactures high-performance computing systems tailored for AI and machine learning tasks, will most likely postpone its plans for an IPO next week due to a probe by a U.S. security committee into UAE-based tech conglomerate G42's minority investment in the company, according to Reuters' scoop https://lnkd.in/e6euqDeV The Committee on Foreign Investment in the United States (CFIUS), which reviews foreign investments over possible national security concerns, is currently looking into G42's commitment to buy $335 million worth of Cerebras' stock by April. G42 made up 83% of the total revenue for Cerebras during the year ended December 31, 2023, according to the filing used by Reuters for its story

A lot of talk yesterday about the lack of Danish IPOs at the #FBV (The Association of Listed Danish Growth Companies) conference. Which leads me to expound on the eternal question: When is it too early to go public? You’re an early-stage biotech company just beginning your first phase I trial. You've meticulously completed the preclinical work, so you see this trial as a formality. However, you urgently need substantial funds for the coming phase II trial to avoid delaying your entire clinical program. But is it too early to go public at the phase I stage? Not necessarily, and here’s why. What truly matters to investors is the value your company can generate with their capital. Achieving clinical proof-of-concept in a phase II trial is a significant value inflection point for any biotech company. The fact that you're still years away from the market is less critical. What’s important is the risk-reward balance of your next step. Investors in publicly traded growth stocks—like the nearly 800 listed on the Spotlight and First North Exchanges in Denmark and Sweden—are well-versed in portfolio diversification. They understand that investing all their savings in a single small growth company is unwise, and they’ve long recognized that being a passive, long-term investor in a company requiring regular capital raises is a losing strategy. Let’s be honest: Most investors aren’t betting on your company’s long-term prospects (I dislike that word "betting," but it’s apt here). They’re focused on your next milestone. If you can convincingly show that you’ve done everything possible to mitigate the risks of this next step, and have prepared thoroughly and professionally, you’ve done your part. The rest is up to the investors. In short, the question of whether your company is IPO-ready isn’t really about risk – if we assume the risk can be explain and perhaps even quantified. It may sound simplistic, but it’s too early to go public if you and your company aren’t ready. You do need to be able to answer critical questions like: Are you running a tight ship? Are you, your board and your senior team ready for the challenges ahead? Are your internal procedures—financial, R&D, communication, governance, salaries, strategies, and everything else—adequately reflective of the grave responsibility of managing other people’s hard-earned money? If you can confidently answer "Yes," then you may indeed be ready, and it might not be too early. The investors can handle the risk - if you just handle everything else. #IPO, #Growthcompanies, #Firstnorth, #Biotech

Geoff Meyerson of Locust Walk, shared insights with Chief Medical Officer 360º on 2024 fundraising and business development trends. Discover how CMOs can enhance investor interactions. Don't miss advice for biotechs & CMOs navigating financing complexities.    Read the full article for a comprehensive overview and strategic outlook: https://lnkd.in/eMWjGXU8    #BiotechTrends #FinancialOutlook #CMOStrategies #InvestorRelations 

The Yale Innovation Summit hosted by Yale Ventures somehow manages to feel like both a cozy meetup with your innovative besties and the region's biggest entrepreneurship event. If you're looking for mentors, partners, investors or even just inspiration from industry leaders, don't miss this year's event! Update: at last count, we have 160+ speakers, 5 keynotes, 5 pitch events across #arts #biotech #climate #health #tech.